{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:20:33Z","timestamp":1762521633097},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T00:00:00Z","timestamp":1384819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00508-013-0460-x","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T01:06:34Z","timestamp":1384823194000},"page":"126-129","source":"Crossref","is-referenced-by-count":6,"title":["Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?"],"prefix":"10.1007","volume":"126","author":[{"given":"Du\u0161anka","family":"Martinovi\u0107 Kaliterna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jure","family":"Aljinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijana","family":"Perkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Marasovi\u0107 Krstulovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivanka","family":"Marinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonko","family":"Vlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"issue":"7","key":"460_CR1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","volume":"8","author":"JE Fonseca","year":"2009","unstructured":"Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538\u201342.","journal-title":"Autoimmun Rev"},{"issue":"24","key":"460_CR2","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","volume":"90","author":"T Tamura","year":"1993","unstructured":"Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA. 1993;90(24):11924\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"460_CR3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","volume":"63","author":"C Alessandri","year":"2004","unstructured":"Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004;63(10):1218\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"460_CR4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/s10165-010-0409-0","volume":"21","author":"SY Kawashiri","year":"2011","unstructured":"Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011;21(4):370\u20134.","journal-title":"Mod Rheumatol"},{"key":"460_CR5","doi-asserted-by":"crossref","unstructured":"Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren\u2019s syndrome. Arthritis Res Ther. 2011;13(5):R170.","DOI":"10.1186\/ar3493"},{"key":"460_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/DDDT.S14099","volume":"4","author":"AM Patel","year":"2010","unstructured":"Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther. 2010;4:263\u201378.","journal-title":"Drug Des Devel Ther"},{"key":"460_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1297-319X(10)70001-4","volume":"77","author":"T Pham","year":"2010","unstructured":"Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, et al. Tocilizumab: therapy and safety management. Joint Bone Spine. 2010;77(Suppl 1):3\u2013100.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"460_CR8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","volume":"50","author":"L Campbell","year":"2011","unstructured":"Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"460_CR9","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011(2):CD008794.","DOI":"10.1002\/14651858.CD008794.pub2"},{"issue":"5","key":"460_CR10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/rheumatology\/ker311","volume":"51","author":"CJ Edwards","year":"2012","unstructured":"Edwards CJ. IL-6 inhibition and infection: treating patients with tocilizumab. Rheumatology (Oxford). 2012;51(5):769\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"460_CR11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","volume":"70","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"460_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002960050070","volume":"18","author":"M Tishler","year":"1999","unstructured":"Tishler M, Yaron I, Shirazi I, Yossipov Y, Yaron M. Increased salivary interleukin-6 levels in patients with primary Sjogren\u2019s syndrome. Rheumatol Int. 1999;18(4):125\u20137.","journal-title":"Rheumatol Int"},{"issue":"12","key":"460_CR13","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","volume":"105","author":"M Tishler","year":"1998","unstructured":"Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjogren syndrome. Ophthalmol. 1998;105(12):2327\u20139.","journal-title":"Ophthalmol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-013-0460-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0460-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:16:34Z","timestamp":1564744594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-013-0460-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":13,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1007\/s00508-013-0460-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,19]]}}}